Skip to main content

Table 3 Response and number of [177Lu]Lu-DOTA-ZOL treatment cycles administered according to the extent of disease

From: [177Lu]Lu-DOTA-ZOL bone pain palliation in patients with skeletal metastases from various cancers: efficacy and safety results

Extent of skeletal metastases

Number of patients (%)

Response according to VAS assessment criteria (number of patients)

Number of cycles administered

Response according to global pain assessment criteria (number of patients)

Number of cycles administered

< 6

2 (5%)

CR-1

2C

PR-2

1st patient-1C

PR-1

1C

 

2nd patient-2C

6–20

17 (42.5%)

CR-5

4 patients-2C, 1 patient-1C

CR-1

2C

PR-9

5 patients-2C, 4 patients-1C

PR-11

8 patients-2C, 3 patients-1C

MR-1

2C

MR-3

2 patients-1C, 1 patient-2C

NR-2

Both patients-1C

NR-2

Both patients-1C

> 20

7 (17.5%)

CR-2

2 patients, 2C

CR-1

2C

PR-4

3 patients-2C, 1 patient-1C

PR-4

3 patients-2C, 1 patient-1C

MR-0

0

MR-1

2C

NR-1

1C

NR-1

1C

Superscan/diffuse

14 (35%)

CR-3

All patients-2C

CR-0

PR-6

5 patients-2C, 1 patient-1C

PR-8

6 patients-2C, 2 patients-1C

MR-4

1 patient-2C, 3 patients-1C

MR-5

3 patients-2C, 2 patients-1C

NR-1

1 patient 1C

NR-1

1C

  1. VAS visual analogue score, CR complete response, PR partial response, MR minimal response, NR no response, C cycles